Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

ABC-MT Agonists of the microprotein BRAWNIN in the treatment of Charcot Marie Tooth disease

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 July 2024 to 30 June 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101157728

What the project is doing

In the project's own words, from its summary on CORDIS.

This project will provide proof of concept for the neuroprotective potential of agonists of the mitochondrial protein BRAWNIN. We have identified that BRAWNIN is an important regulator of mitochondrial function in neurons. Mitochondria are essential organelles to support metabolic homeostasis in the cell. Mounting evidence in the literature demonstrate that mitochondria and more broadly metabolic regulation is central to the function of the nervous system.

Axons are especially affected by metabolic deregulation, which can lead to axonal degeneration. In this application, we propose that increasing the cellular levels of protein BRAWNIN using a gene-therapy strategy (defined as BRAWNIN agonists) will be protective in neurodegenerative disease, and we will demonstrate this in models of Charcot Marie Tooth disease, a peripheral neuropathy strongly associated with altered metabolism and mitochondria.

Overall, our project will provide the first demonstration that BRAWNIN is a target of therapeutic interest in axonal metabolic diseases, which we will further develop with the ultimate goal to develop BRAWNIN agonists for patients.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI